X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-01 | LUNG | Sung Derrick | CFO | S - Sale+OE | $25.91 | -458 | 255,962 | 0% | -$11,867 | |||||
| D | 2022-03-01 | LUNG | Rose Geoffrey Beran | Chief Commercial Officer | S - Sale+OE | $25.91 | -426 | 154,702 | 0% | -$11,038 | |||||
| D | 2022-03-01 | LUNG | Lehman David Aaron | GC | S - Sale+OE | $25.91 | -458 | 47,376 | -1% | -$11,867 | |||||
| D | 2022-03-01 | LUNG | French Glendon E. III | Pres, CEO | S - Sale+OE | $25.91 | -1,132 | 1,132,517 | 0% | -$29,330 | |||||
| M | 2022-02-17 | LUNG | French Glendon E. III | Pres, CEO | S - Sale | $27.07 | -25,000 | 1,063,949 | -2% | -$676,635 | |||||
| M | 2022-01-20 | LUNG | French Glendon E. III | Pres, CEO | S - Sale | $25.11 | -25,000 | 1,088,949 | -2% | -$627,696 | |||||
2021-12-16 | LUNG | French Glendon E. III | Pres, CEO | S - Sale | $31.05 | -25,000 | 1,113,949 | -2% | -$776,220 | ||||||
2021-12-15 | LUNG | Rose Geoffrey Beran | Chief Commercial Officer | S - Sale | $30.55 | -22,000 | 123,459 | -15% | -$672,002 | ||||||
| M | 2021-12-14 | LUNG | Sung Derrick | CFO | S - Sale | $31.71 | -6,000 | 225,420 | -3% | -$190,255 | |||||
2021-12-01 | LUNG | French Glendon E. III | Pres, CEO | S - Sale | $32.73 | -1,421 | 1,138,949 | 0% | -$46,509 | ||||||
| AD | 2021-05-20 | LUNG | French Glendon E. III | Pres, CEO | S - Sale+OE | $41.95 | -25,000 | 1,234,884 | -2% | -$1,048,780 | |||||
| AD | 2021-04-15 | LUNG | French Glendon E. III | Pres, CEO | S - Sale+OE | $43.75 | -25,000 | 1,249,884 | -2% | -$1,093,856 | |||||
2021-12-01 | LUNG | Lehman David Aaron | GC | S - Sale | $32.73 | -383 | 16,834 | -2% | -$12,536 | ||||||
2021-12-01 | LUNG | Rose Geoffrey Beran | Chief Commercial Officer | S - Sale | $32.73 | -355 | 145,459 | 0% | -$11,619 | ||||||
2021-12-01 | LUNG | Sung Derrick | CFO | S - Sale | $32.73 | -383 | 231,420 | 0% | -$12,536 | ||||||
2021-11-18 | LUNG | French Glendon E. III | Pres, CEO | S - Sale | $35.98 | -25,000 | 1,105,370 | -2% | -$899,471 | ||||||
2021-11-15 | LUNG | Rose Geoffrey Beran | Chief Commercial Officer | S - Sale | $39.94 | -7,000 | 145,814 | -5% | -$279,580 | ||||||
2021-10-21 | LUNG | French Glendon E. III | Pres, CEO | S - Sale | $39.75 | -25,000 | 1,130,370 | -2% | -$993,681 | ||||||
2021-10-15 | LUNG | Rose Geoffrey Beran | Chief Commercial Officer | S - Sale | $39.44 | -7,000 | 152,814 | -4% | -$276,080 | ||||||
| M | 2021-09-20 | LUNG | Sung Derrick | CFO | S - Sale | $37.43 | -6,000 | 231,803 | -3% | -$224,562 | |||||
| M | 2021-09-16 | LUNG | French Glendon E. III | Pres, CEO | S - Sale | $38.13 | -48,571 | 1,155,370 | -4% | -$1,852,124 | |||||
2021-09-15 | LUNG | Rose Geoffrey Beran | Chief Commercial Officer | S - Sale | $38.12 | -7,000 | 159,814 | -4% | -$266,840 | ||||||
2021-09-01 | LUNG | Sung Derrick | CFO | S - Sale | $40.09 | -383 | 237,803 | 0% | -$15,354 | ||||||
2021-09-01 | LUNG | Rose Geoffrey Beran | Chief Commercial Officer | S - Sale | $40.09 | -355 | 166,814 | 0% | -$14,232 | ||||||
2021-09-01 | LUNG | Lehman David Aaron | GC | S - Sale | $40.09 | -383 | 17,217 | -2% | -$15,354 | ||||||
2021-09-01 | LUNG | French Glendon E. III | Pres, CEO | S - Sale | $40.09 | -1,421 | 1,203,941 | 0% | -$56,968 | ||||||
2021-08-19 | LUNG | French Glendon E. III | Pres, CEO | S - Sale | $36.63 | -26,000 | 1,205,362 | -2% | -$952,340 | ||||||
2021-08-16 | LUNG | Rose Geoffrey Beran | Chief Commercial Officer | S - Sale | $36.71 | -7,000 | 166,885 | -4% | -$256,970 | ||||||
2021-07-15 | LUNG | Rose Geoffrey Beran | Chief Commercial Officer | S - Sale | $38.73 | -7,000 | 173,885 | -4% | -$271,080 | ||||||
| D | 2021-07-15 | LUNG | French Glendon E. III | Pres, CEO | S - Sale+OE | $38.73 | -26,000 | 1,231,305 | -2% | -$1,006,906 | |||||
2021-07-13 | LUNG | Boston Scientific Corp | 10% | S - Sale | $37.45 | -2,500,000 | 1,488,106 | -63% | -$93,625,000 | ||||||
2021-07-12 | LUNG | Florin Daniel P | Dir | P - Purchase | $40.00 | +2,500 | 23,321 | +12% | +$100,000 | ||||||
2021-06-25 | LUNG | Florin Daniel P | Dir | P - Purchase | $44.12 | +2,222 | 20,821 | +12% | +$98,035 | ||||||
| D | 2021-06-17 | LUNG | French Glendon E. III | Pres, CEO | S - Sale+OE | $42.95 | -26,000 | 1,252,930 | -2% | -$1,116,585 | |||||
2021-05-24 | LUNG | Rose Geoffrey Beran | Chief Commercial Officer | S - Sale | $40.88 | -4,797 | 163,285 | -3% | -$196,085 | ||||||
2021-05-20 | LUNG | French Glendon E. III | Pres, CEO | S - Sale | $41.91 | -26,000 | 1,226,455 | -2% | -$1,089,530 | ||||||
2021-05-10 | LUNG | Rose Geoffrey Beran | Chief Commercial Officer | S - Sale | $40.70 | -4,797 | 116,673 | -4% | -$195,247 | ||||||
2021-04-19 | LUNG | Rose Geoffrey Beran | Chief Commercial Officer | S - Sale | $43.24 | -4,797 | 121,470 | -4% | -$207,422 | ||||||
2021-04-15 | LUNG | French Glendon E. III | Pres, CEO | S - Sale | $43.75 | -26,000 | 1,252,455 | -2% | -$1,137,556 | ||||||
2021-04-06 | LUNG | Boston Scientific Corp | 10% | S - Sale | $43.60 | -650,000 | 3,988,106 | -14% | -$28,340,000 | ||||||
| A | 2021-04-05 | LUNG | Rose Geoffrey Beran | Chief Commercial Officer | S - Sale | $47.65 | -4,797 | 104,267 | -4% | -$228,557 | |||||
2021-04-05 | LUNG | Rose Geoffrey Beran | Chief Commercial Officer | S - Sale | $47.64 | -4,797 | 109,064 | -4% | -$228,521 | ||||||
| M | 2021-04-05 | LUNG | Sung Derrick | CFO | S - Sale | $47.36 | -10,000 | 218,659 | -4% | -$473,622 | |||||
2021-03-30 | LUNG | Boston Scientific Corp | 10% | S - Sale | $40.80 | -1,350,000 | 4,638,106 | -23% | -$55,080,000 | ||||||
2020-10-05 | LUNG | Florin Daniel P | Dir | P - Purchase | $19.00 | +15,789 | 15,789 | New | +$299,991 | ||||||
| D | 2020-10-05 | LUNG | Ferrari Richard M | Dir | P - Purchase | $19.00 | +13,157 | 1,248,508 | +1% | +$249,983 | |||||
2020-10-05 | LUNG | Melenikiotou Georgia | Dir | P - Purchase | $19.00 | +26,315 | 26,315 | New | +$499,985 | ||||||
| D | 2020-10-05 | LUNG | Mead Dana G Jr. | Dir | P - Purchase | $19.00 | +26,315 | 1,550,424 | +2% | +$499,985 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |